Search research articles
Contact Us
Filters
Showing results (11-20 of 52) with videos related to
Page
of 6
Sort By:
Biological Psychiatry
|
November 7, 2008
A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia
W Wolfgang Fleischhacker, Robert D McQuade, Ronald N Marcus, et al.
Journal of Clinical Psychopharmacology
|
March 18, 2008
Aripiprazole efficacy in irritability and disruptive-aggressive symptoms: young mania rating scale line analysis from two, randomized, double-blind, placebo-controlled trials
Mark A Frye, James Eudicone, Andrei Pikalov, et al.
Schizophrenia Research
|
November 29, 2008
Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study
Matthew J Byerly, Ronald N Marcus, Quynh-Van Tran, et al.
The Journal of Clinical Psychiatry
|
March 6, 2007
Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine
John M Kane, Herbert Y Meltzer, William H Carson, et al.
Journal of Affective Disorders
|
February 24, 2009
The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials
Ira D Glick, Raymond Mankoski, James M Eudicone, et al.
CNS Spectrums
|
September 2, 2006
The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia
Andrew J Cutler, Ronald N Marcus, Sterling A Hardy, et al.
Journal of Clinical Psychopharmacology
|
April 7, 2007
Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole
Dan L Zimbroff, Ronald N Marcus, George Manos, et al.
Journal of the American Academy of Child and Adolescent Psychiatry
|
October 3, 2009
A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder
Ronald N Marcus, Randall Owen, Lisa Kamen, et al.
Schizophrenia Research
|
July 24, 2007
Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks
John M Kane, David T Crandall, Ronald N Marcus, et al.
The Journal of Clinical Psychiatry
|
February 8, 2007
Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial
Tram K Tran-Johnson, David A Sack, Ronald N Marcus, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 52) with videos related to
Sort By:
Page
of 6
Biological Psychiatry
|
November 7, 2008
A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia
W Wolfgang Fleischhacker, Robert D McQuade, Ronald N Marcus, et al.
Journal of Clinical Psychopharmacology
|
March 18, 2008
Aripiprazole efficacy in irritability and disruptive-aggressive symptoms: young mania rating scale line analysis from two, randomized, double-blind, placebo-controlled trials
Mark A Frye, James Eudicone, Andrei Pikalov, et al.
Schizophrenia Research
|
November 29, 2008
Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study
Matthew J Byerly, Ronald N Marcus, Quynh-Van Tran, et al.
The Journal of Clinical Psychiatry
|
March 6, 2007
Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine
John M Kane, Herbert Y Meltzer, William H Carson, et al.
Journal of Affective Disorders
|
February 24, 2009
The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials
Ira D Glick, Raymond Mankoski, James M Eudicone, et al.
CNS Spectrums
|
September 2, 2006
The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia
Andrew J Cutler, Ronald N Marcus, Sterling A Hardy, et al.
Journal of Clinical Psychopharmacology
|
April 7, 2007
Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole
Dan L Zimbroff, Ronald N Marcus, George Manos, et al.
Journal of the American Academy of Child and Adolescent Psychiatry
|
October 3, 2009
A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder
Ronald N Marcus, Randall Owen, Lisa Kamen, et al.
Schizophrenia Research
|
July 24, 2007
Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks
John M Kane, David T Crandall, Ronald N Marcus, et al.
The Journal of Clinical Psychiatry
|
February 8, 2007
Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial
Tram K Tran-Johnson, David A Sack, Ronald N Marcus, et al.
Page
of 6